What is venture debt and how does TriplePoint use it?

Venture debt is financing for startups that have raised VC equity funding; lenders provide loans secured by company assets (IP, accounts receivable) to startups wanting capital without diluting shareholders. Why startups use it: a startup that raised $20M in Series B equity at $100M valuation needs $5M more to reach the next milestone; borrowing $5M at 12% interest preserves upside for existing shareholders versus selling equity at current valuation. What TPVG charges: 10-15% interest rates (often floating), origination fees of 0.5-2%, end-of-term payments of 1-5%, and warrants (options to buy equity representing 0.5-3% of loan amount in equity value). Why rates are high: startups cannot borrow from banks (banks require profitable cash flow); TPVG accepts risk banks won't; high rates compensate for the possibility the startup fails before reaching profitability.

What is Skyclarys and what is the Friedreich's ataxia market?

Friedreich's ataxia is a rare progressive neurological disease caused by FXN gene mutations reducing frataxin protein, which leads to mitochondrial iron accumulation, neuronal damage, progressive loss of coordination, wheelchair dependence (typically by 20s-30s), and cardiomyopathy; approximately 1 in 50,000 people globally (~6,000-10,000 U.S. patients). Skyclarys (omaveloxolone): FDA approved in February 2023 as the first-ever approved treatment for FA; activates the Nrf2 oxidative stress response pathway; in the MOXIe trial significantly improved neurological function scores versus placebo in patients 16 and older; slows neurological decline rather than curing FA. Commercial potential: priced at approximately $370,000/year per patient; even at modest penetration, annual revenue could reach hundreds of millions; Skyclarys is PTC's primary U.S. growth driver.

What is a Business Development Company (BDC) and why do they pay high dividends?

BDC structure: created by Congress in 1980 to channel capital to small and mid-size U.S. businesses; BDCs are publicly traded investment companies that invest in debt and equity of private or small public companies. Tax treatment and dividends: BDCs elect pass-through tax treatment similar to REITs; distributing 90%+ of investment income means no corporate income tax at the BDC level; income flows directly to shareholders. Why yields are high: BDC loan portfolios earn 10-15% interest rates on venture or middle-market loans; after leverage costs (BDCs borrow at 5-7%), net yield on equity is 8-12%; the regulatory pass-through forces BDCs to pay this out as dividends. TPVG specifically: focusing on venture-backed growth companies (earlier stage, higher risk) versus established middle-market companies; higher risk is compensated by higher interest rates and warrant upside flowing through to dividends.

brimindinvest.com / compare / ptct-vs-tpvgLIVE

PTCT

PTC Therapeutics, Inc. · Healthcare - Biopharmaceuticals / Rare Diseases

$78.98

+12.33% this month

VERSUS

⟷

COMPARE

TPVG

TriplePoint Venture Growth BDC Corp. · Financial Services - Business Development Company / Venture Debt

$5.00

-7.23% this month

Scoreboard verdict

Across AI score, momentum, valuation, upside, operating margin

PTCT

2

TPVG

2

MIXED SETUP

Comparison scoreboard

MIXED SETUP

AI Score

PTCT ✓51.9

TPVG 24.6

1Y Return

PTCT ✓+56.61%

TPVG -12.49%

Fwd P/E

PTCT 28.38

TPVG ✓6.08

Target Up.

PTCT +18.93%

TPVG ✓+23.33%

Op. Margin

PTCT N/A

TPVG N/A

Metrics last refreshed: 6/20/2026

Quick take

PTCT vs TPVG Stock Comparison: AI Score, Valuation, Performance and Upside

PTCT (PTC Therapeutics) and TPVG (TriplePoint Venture Growth) are unrelated businesses — PTC is a rare disease biopharmaceutical company with Skyclarys (Friedreich's ataxia), Emflaza (DMD), and international Translarna revenues, while TPVG is a BDC providing venture debt to VC-backed companies and paying high dividend income. PTC appeals to biotech investors seeking rare disease pipeline value; TPVG appeals to income investors seeking 8-12% dividend yields.

PTCT vs TPVG is rare disease biopharmaceutical with first-in-class Friedreich's ataxia treatment and RNA platform pipeline (PTC Therapeutics' Skyclarys commercial launch, Emflaza DMD revenue, and long-running Translarna international business — navigating FDA regulatory challenges and rare disease competition) versus high-yield venture debt BDC paying 8-12% dividends (TriplePoint Venture Growth's loan portfolio to VC-backed life sciences and tech companies — earning interest income and warrant upside while accepting venture default risk) — biopharmaceutical capital appreciation versus specialty finance income.

Live analysis · updated 6/20/2026

PTCT and TPVG are closely matched — they split the tracked metrics evenly. PTCT has delivered stronger 1-year price return (+56.61% vs -12.49%), though TPVG trades at the lower forward P/E (6.08x vs 28.38x). Analyst consensus implies meaningfully more upside for TPVG (+23.33%) than for PTCT (+18.93%).

Normalized 1Y performance

PTCT

TPVG

Recent returns

PTCT

TPVG

Analyst price targets & sentiment

PTCT · 14 analysts

STRONG BUYHOLDSTRONG SELL

Buy (1.9/5.0)

Price target range

analyst low$65.00
analyst high$124.00
analyst mean$93.93
current price$78.98

+18.9% upside to analyst mean

TPVG · 3 analysts

STRONG BUYHOLDSTRONG SELL

Hold (3.0/5.0)

Price target range

analyst low$5.50
analyst high$7.00
analyst mean$6.17
current price$5.00

+23.3% upside to analyst mean

Who should consider this stock?

PTCT may suit investors who:

→Believe Skyclarys (Friedreich's ataxia) launch success will establish PTC as a multi-product rare disease company with a substantially larger U.S. revenue base
→See PTC's RNA-targeting scientific platform as generating multiple future rare genetic disease pipeline opportunities
→Are willing to accept binary clinical milestones and Translarna FDA rejection risk in exchange for rare disease exposure at a potentially below-NAV valuation

TPVG may suit investors who:

→Seek high current dividend income (8-12% yield) from a specialty venture lender with life sciences and technology expertise
→Believe TriplePoint's top-tier VC firm relationships provide access to high-quality borrowers with lower-than-average default rates
→Want equity-upside participation in venture-backed company success through the warrant component alongside fixed income from loan interest payments

Performance & AI score

Metric	PTCT	TPVG
AI score	51.9	24.6
AI rank	#357	#3052
Latest close	$78.98	$5.00
1M return	+12.33%	-7.23%
6M return	+5.39%	-11.62%
1Y return	+56.61%	-12.49%

$10,000 invested — hypothetical growth (dividends reinvested)

How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?

Period	PTCT	TPVG
1Y ago	$15.66K (+56.6%) started 2025-06-18	$10.4K (+4.0%) started 2025-06-18
5Y ago	$17.69K (+76.9%) started 2021-06-18	$18.84K (+88.4%) started 2021-06-18
10Y ago	$113.15K (+1031.5%) started 2016-06-20	$220.25K (+2102.5%) started 2016-06-20

Hypothetical — past performance does not guarantee future results.

Valuation & upside potential

Metric	PTCT	TPVG
Market cap	$6.55B	$202.99M
Trailing P/E	N/A	4.76
Forward P/E	28.38	6.08
Price/Sales	7.92	2.24
EV/Revenue	8.35	7.12
Analyst target	$93.93	$6.17
Target upside	+18.93%	+23.33%

Growth, profitability & risk

Metric	PTCT	TPVG
Revenue growth	-76.80%	1.40%
Earnings growth	N/A	-51.90%
EPS growth	N/A	-51.90%
FCF margin	-50.55%	+37.73%
Operating margin	N/A	N/A
Profit margin	-22.58%	47.08%
ROIC proxy	N/A	12.23%
Return on equity	N/A	12.23%
Dividend yield	0.00%	18.32%
Beta	0.55	1.33
Debt/equity	N/A	127.12
Current ratio	2.44	1.94
Quick ratio	2.29	0.97

Drawdown & downside risk

Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.

1Y risk snapshot

PTCT max drawdown27.17%

TPVG max drawdown31.61%

PTCT max wkly drop17.13%

TPVG max wkly drop11.72%

5Y risk snapshot

PTCT max drawdown69.42%

TPVG max drawdown54.79%

PTCT max wkly drop39.59%

TPVG max wkly drop17.71%

10Y risk snapshot

PTCT max drawdown73.78%

TPVG max drawdown81.78%

PTCT max wkly drop48.27%

TPVG max wkly drop71.51%

Performance metrics by period

Period	Metric	PTCT	TPVG
1Y	Growth	+56.61%	-12.49%
	CAGR	+56.66%	-12.50%
	Sharpe ratio	1.16	-0.40
	Max drawdown	27.17%	31.61%
	Max daily drop	9.89%	8.26%
	Max wkly drop	17.13%	11.72%
5Y	Growth	+76.93%	-32.22%
	CAGR	+12.09%	-7.49%
	Sharpe ratio	0.40	-0.23
	Max drawdown	69.42%	54.79%
	Max daily drop	29.77%	12.33%
	Max wkly drop	39.59%	17.71%
10Y	Growth	+1031.52%	+70.87%
	CAGR	+27.48%	+5.51%
	Sharpe ratio	0.62	0.25
	Max drawdown	73.78%	81.78%
	Max daily drop	39.94%	45.49%
	Max wkly drop	48.27%	71.51%

Business comparison

Category	PTCT	TPVG
Company	PTC Therapeutics, Inc.	TriplePoint Venture Growth BDC Corp.
Sector	Healthcare - Biopharmaceuticals / Rare Diseases	Financial Services - Business Development Company / Venture Debt
Industry	N/A	N/A
Core business	PTC Therapeutics is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases. Products include Translarna (ataluren) for nonsense mutation Duchenne muscular dystrophy (DMD) — approved in the EU but not the U.S.; Emflaza (deflazacort) for Duchenne muscular dystrophy — approved in the U.S.; Skyclarys (omaveloxolone) — the first FDA-approved treatment for Friedreich's ataxia (approved February 2023); and pipeline candidates for alpha-1 antitrypsin deficiency and other rare conditions. PTC's scientific platform focuses on post-transcriptional regulatory mechanisms (splicing, nonsense mutation readthrough) that enable RNA-targeting therapeutic approaches.	TriplePoint Venture Growth BDC is a specialty finance company (Business Development Company) providing venture lending — secured loans, equipment financing, and revolving credit facilities — to growth-stage companies that have raised venture capital. TPVG's borrowers are VC-backed startups and growth companies in life sciences and technology seeking non-dilutive capital between equity funding rounds. TPVG earns interest income on its loan portfolio and charges origination fees; as a BDC, TPVG distributes substantially all income to shareholders as dividends, typically yielding 8-12% annually.
Investor focus	Investors track PTC's revenue from its commercial portfolio (particularly Skyclarys launch trajectory), clinical pipeline milestones, cash burn and runway, and prospects for U.S. Translarna approval (repeatedly rejected by FDA; approved in EU).	Investors track TPVG's net investment income (NII) per share, portfolio credit quality (default losses on venture loans), end-of-term payments and prepayments, and net asset value (NAV) per share.

PTCT strengths

→Skyclarys (Friedreich's ataxia) is the first FDA-approved treatment for FA — positioning PTC as the commercial leader in a disease with no prior approved therapy; orphan drug pricing and 7-year exclusivity provide strong economic protection
→Multiple commercial products provide revenue foundation — Translarna (ex-U.S.) and Emflaza (U.S.) generate ongoing cash flow reducing binary pipeline dependency
→Friedreich's ataxia patient community is highly motivated and organized, supporting reimbursement advocacy — the FA patient community has been waiting decades for an approved therapy; strong patient advocacy supports payer coverage decisions

TPVG strengths

→Venture debt provides high current income with equity upside through warrants — loan interest rates of 10-14% plus warrants in borrowers; if borrowers succeed and go public or are acquired, warrant value adds to returns
→BDC pass-through structure provides tax transparency and high dividend yield — TPVG distributes nearly all income as dividends; historically 8-12% yield attractive for income-focused investors
→Life sciences and technology expertise aligns TPVG with high-quality VC dealflow — TriplePoint Capital's deep VC relationships provide access to top-tier venture-backed borrowers with lower-than-average default rates

Risks to watch — PTCT

→Translarna has faced repeated FDA rejection for U.S. approval — U.S. approval would dramatically expand the addressable market but regulatory pathway has been elusive after multiple attempts
→Rare disease competition is intensifying as large biotechs and gene therapy companies target DMD — Sarepta Therapeutics has exon-skipping therapies and gene therapy for DMD; commercial competition limits Emflaza's market position
→Cash burn from pipeline development and Skyclarys commercial launch requires financing discipline — PTC is not yet fully self-funding; continued investment in launch activities requires careful cash management

Risks to watch — TPVG

→Venture-backed company defaults are the primary credit risk — if borrowers fail (startup fails, VC backing stops), TPVG may recover less than loan value from secured collateral; default rates depend on the macro environment and VC funding availability
→Interest rate environment affects BDC returns and valuations — rising rates increase TPVG's borrowing costs; falling rates reduce income on floating-rate loans and depress dividends
→External management structure creates potential conflicts of interest — TriplePoint Capital manages TPVG and earns management fees; the structure may not always align manager incentives with TPVG shareholder interests

Frequently asked questions

DMD is a severe, progressive, X-linked genetic disease caused by mutations in the dystrophin gene; without functional dystrophin, muscle fibers break down with each contraction causing progressive wasting. Affected population: approximately 1 in 3,500-5,000 male births globally; diagnosis typically at 3-5 years old when parents notice delayed walking. Progression: boys typically lose ability to walk by age 10-12; respiratory failure (the leading cause of death) and cardiomyopathy follow; median life expectancy without treatment was approximately 25-30 years (improved to 30s-40s with modern respiratory care). Pharma market importance: devastating unmet need; orphan drug designation provides 7-year exclusivity and 50% tax credit on clinical trial costs; pricing power is significant because families and insurers pay substantially for meaningful benefit.

AI Prediction SignalNext 5 trading days

Members only

PTCT

+2.8%BUY

TPVG

+1.1%HOLD

Start Free Trial Log in

ML model trained on historical prices · 14-day free trial · No credit card required

Free public comparison

Want deeper AI forecasts?

This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.

Start Free Trial Read Investing Guides